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ABSTRACT Phosphorylation of ribosomal protein S6 in
NIH 3T3 fibroblasts is dependent on the presence of serum,
but after transformation of these cells by Abelson murine leu-
kemia virus (Ab-MuLV), S6 remained highly phosphorylated
on serine residues either in the absence or the presence of se-
rum. To investigate whether S6 phosphorylation in this system
was a consequence of the action of the Ab-MuLV tyrosine-spe-
cific protein kinase, purified Ab-MuLV kinase made in Esche-
richia coli was microinjected into Xenopus oocytes and was ob-
served to cause a 7- to 15-fold increase in the phosphorylation
of S6 on serine residues. Two-dimensional phosphopeptide
maps of S6 phosphorylated in Ab-MuLV-transformed NIH
cells in the absence of serum were identical to those of S6 iso-
lated from normal cells grown in the presence of serum. In
addition, S6 from oocytes injected with Ab-MuLV kinase
yielded an S6 phosphopeptide map indistinguishable from that
of serum-stimulated NIH 3T3 cells, whereas S6 from control
oocytes lacked several phosphopeptides. Ab-MuLV kinase did
not phosphorylate S6 directly in vitro, and microinjection of a
mutant Ab-MuLV protein lacking kinase activity had no ef-
fect. These results indicate that the Ab-MuLV kinase interacts
with a cellular pathway to enhance S6 phosphorylation by di-
rectly or indirectly activating an S6 protein kinase and/or in-
activating an S6 protein phosphatase.
Tyrosine-specific protein kinases are encoded by the trans-
forming gene products of several retroviruses (1-9). Similar
kinase activities are found also in association with the mem-
brane receptors for epidermal growth factor (EGF) (10),
platelet-derived growth factor (PDGF) (11), insulin-like
growth factor (12, 13), and insulin (14). These findings have
suggested that phosphorylation of proteins on tyrosine resi-
dues is involved in the control of cell growth by transforming
gene products as well as normal cellular growth factors.
However, physiologically important substrates for these en-
zymes have yet to be identified in any of these systems. Al-
though all of the above protein kinases appear to be specific
for tyrosine residues in vitro, the addition of epidermal
growth factor (15), platelet-derived growth factor (16), or in-
sulin (15, 17, 18) to responsive cells also results in increased
phosphorylation of certain proteins on serine residues. Simi-
larly, in cells transformed by either Rous sarcoma virus
(RSV) or Abelson murine leukemia virus (Ab-MuLV), both
of which encode tyrosine-specific protein kinases, an in-
crease in protein-bound phosphoserine has been observed
(19, 20). Among these phosphoseryl-proteins, ribosomal pro-
tein S6 is of particular interest because its phosphorylation is
correlated with growth-promoting stimuli in a wide variety of
systems, including serum- and growth factor-induced cell
proliferation (15, 21, 22), Xenopus oocyte maturation or fer-
tilization (23-25), regenerating rat liver (26), viral infection
(27), and viral transformation (20). In the case of cells trans-
formed with a temperature-sensitive transformation mutant
of RSV, enhanced phosphorylation of S6 on serine residues
is also temperature sensitive (20).
The widespread correlation between S6 phosphorylation
and the growth-promoting actions of such a diverse group of
agents suggests that S6 phosphorylation plays an important
role in regulating growth. The precise function of S6 phos-
phorylation in protein synthesis or cell growth has not yet
been elucidated, but S6 can be crosslinked to synthetic
mRNAs on the ribosome, implying a role in mRNA binding
(28). Phosphorylation of S6 has been shown to affect both
the binding and translation efficiency of poly(A,U,G) in a
reconstituted protein synthesis system (29). Ribosomes con-
taining the maximally phosphorylated derivative of S6 (4-5
mol of phosphate per mol of S6) are preferentially incorpo-
rated into new polyribosomes following serum stimulation of
3T3 cells (15, 30), suggesting that early growth-promoting
mRNAs may be selectively translated by phosphorylated ri-
bosomes. This idea has been supported by studies in Dro-
sophila cells subjected to heat shock, which causes rapid S6
dephosphorylation and results in ribosomes that are unable
to translate specific mRNAs in vitro (31, 32). These results
indicate that S6 phosphorylation may play a role in recruit-
ment of specific mRNAs and enhanced synthesis of certain
proteins.
In normal Swiss mouse 3T3 fibroblasts, phosphorylation
of S6 is dependent on the presence of exogenous serum or
growth factors in the medium (15). In this report, we demon-
strate that in Ab-MuLV-transformed NIH 3T3 fibroblasts
(cell line ANN-i), S6 is constitutively phosphorylated in the
presence or absence of serum. Little is known about the
enzymology of S6 phosphorylation, but the fact that growth-
promoting agents associated with tyrosine-specific protein
kinases enhance S6 phosphorylation on seine residues im-
plies that such tyrosyl-protein kinases are capable of regulat-
ing the enzymes that control S6 phosphorylation. One ap-
proach to the study of this interaction is to introduce a tyro-
sine-specific protein kinase into a normal cell. A suitable cell
for such experiments is the Xenopus oocyte, which can be
injected with 0.1-,l volumes. The phosphorylation of Xeno-
pus S6 has been shown to be increased during oocyte matu-
ration induced by either progesterone or insulin (24, 25) and
in response to microinjection of either the maturation-pro-
moting factor (24) or the transforming protein of RSV (33).
Abbreviations: MuLV, murine leukemia virus; Ab-MuLV, Abelson
MuLV; Mo-MuLV, Moloney MuLV; RSV, Rous sarcoma virus.
§Present address: National Institute for Medical Research, Mill Hill,
London, NW7 1AA, England, U.K.
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
272
Proc. NatL Acad. Sci. USA 82 (1985) 273
MATERIALS AND METHODS
Isolation of oocytes, microinjection, radiolabeling, and prep-
aration of oocyte phosphorylated ribosomes were carried
out as described (25, 34). NIH 3T3 fibroblasts and ANN-1
fibroblasts were grown in Dulbecco's modified Eagle's me-
dium (DME medium) with 10% calf serum. The night before
being labeled, cells were plated with 10% serum at 1 x 106
cells per 10-cm dish. The cells were then washed two or
three times in DME medium, incubated for 4 hr, and washed
twice in phosphate-free DME medium-all in the absence of
serum. Labeling was carried out in 3 ml of phosphate-free
DME medium containing 3 mCi (1 Ci = 37 GBq) of 32p, (New
England Nuclear) for 2 hr with or without 10% dialyzed calf
serum for the last hour. The cells were washed in ice-cold
phosphate-buffered saline and were lysed in 2.0 ml of 50 mM
Pipes, pH 7.5/5 mM MgCl2/5 mM KCI/50 mM NaF/40 AM
EDTA/1% (wt/vol) deoxycholate/1% (wt/vol) Triton X-
100. Extracts were clarified by microcentrifugation (13,000
x g for 10 min) and layered over 2.0 ml of 1.6 M sucrose/50
mM Pipes, pH 7.5/5 mM MgCl2/0.5 M KCI/40 ,uM EDTA,
and the ribosomes were pelleted by centrifugation (160,000
x g at 2°C for 4.5 hr).
For identification of S6 and determination of the extent of
its phosphorylation, the ribosomes were suspended and the
ribosomal proteins were extracted, precipitated, and sub-jected to two-dimensional gel electrophoresis by the proce-
dure of Thomas et al. (15) in the presence of carrier ribosom-
al proteins from Xenopus oocytes (unphosphorylated S6)
and unfertilized eggs (phosphorylated S6). The labeled S6
was localized by autoradiography, and the ribosomal pro-
teins were visualized by staining with Coomassie blue. For
phosphopeptide analysis, the ribosomes were suspended in
H20, heated to 95°C for 3 min in electrophoresis sample
buffer (0.07 M Tris, pH 6.8/11% glycerol/3% NaDod-
S04/5% 2-mercaptoethanol/0.002% bromophenol blue), and
subjected to electrophoresis through a 12.5% NaDod-
S04/polyacrylamide gel. S6 was located by autoradiogra-
phy, eluted, precipitated with trichloroacetic acid, and hy-
drolyzed with trypsin under the conditions described by
Martin-Perez et al. (35) or with chymotrypsin. The phospho-
peptides were resolved by electrophoresis on 20 x 20 cm
thin-layer cellulose sheets (Kodak) for 45 min in the first di-
mension (pH 1.5, 760V) and 50 min in the second dimension
(pH 3.5, 760V). Phosphoamino acid analysis was carried out
as described (1, 3).
The Ab-MuLV-encoded protein kinase was purified from
Escherichia coli carrying a vector designed to allow expres-
sion of sequences, termed v-abl, that encode the Ab-MuLV
kinase activity. Construction of the vector will be published
in detail elsewhere. Briefly, the vector pCS4 (36) contains
the PR promoter of bacteriophage X, a ribosome-binding se-
quence, and an ATG codon followed by 0.24 kilobase pair of
sequences coding for the small tumor antigen of simian virus
40. A temperature-sensitive cI gene of bacteriophage X is
also present so that transcription is repressed at 30°C and
induced at 42°C. To this vector we added 1.2 kilobase pairs
of v-abl sequences coding for a specific NH2-terminal region
of the Ab-MuLV-encoded kinase [from the HincII site at the
Moloney murine leukemia virus (Mo-MuLV)/Ab-MuLV
DNAjunction to the next Pst I site]. This construct produces
a fusion protein consisting of 80 amino acids of the small
tumor antigen and 404 amino acids of the kinase but lacks
any sequences derived from the gag region of Mo-MuLV.
The function of the small tumor antigen is to increase the
amount of protein produced in bacteria. For control experi-
ments, a fusion protein was constructed with the same vec-
tor, but 53 amino acid residues of the kinase portion were
deleted (terminating at the first Sac I site in the v-abl gene),
resulting in a product that was kinase defective. Purification
of the active kinase (unpublished data) involves a combina-
tion of conventional chromatography (DEAE-cellulose, hy-
droxylapatite, Affi-Gel blue), HPLC, and use of a column
coupled to a monoclonal antibody directed towards phos-
photyrosine (37). This column adsorbs many of the phospho-
tyrosyl proteins present in Ab-MuLV-transformed cells (37).
Since the Ab-MuLV kinase undergoes autophosphorylation
on tyrosine, the kinase binds to the monoclonal column and
can be eluted by the addition ofpara-nitrophenyl phosphate,
a phosphotyrosine analog. At 100 AM ATP and 1 mg of angi-
otensin II (used as an artificial substrate) per ml, the specific
activity of the purified enzyme at 30'C was -2.0 ,Amol/min
per mg. For microinjection experiments in which partially
purified preparations were used (see Fig. 2), the bacteria
were lysed by sonication, extracts were clarified by centrifu-
gation (190,000 x g for 45 min), subjected to batchwise chro-
matography on DEAE-cellulose (20-100 mM NaCl, pH 8.2),
concentrated in an Amicon stirred cell (YM10 membrane),
and finally dialyzed against 40% ethylene glycol/1 mM di-
thiothreitol/0.1 mM EDTA/50 mM Pipes, pH 7.5.
RESULTS
Previously, it had been reported that transformation of cells
by RSV results in the phosphorylation of S6 becoming inde-
pendent of the presence of serum (20). To determine whether
Ab-MuLV has a similar effect, NIH 3T3 fibroblasts and Ab-
MuLV-transformed fibroblasts were serum-starved, labeled
with 32p;, and then incubated for 1 hr in the presence or ab-
sence of serum. Ribosomes were isolated, and the ribosomal
proteins were subjected to two-dimensional gel electropho-
resis by a system developed for ribosomal proteins (15). In
this system, the phosphorylated derivatives of S6 can be re-
solved into discrete spots designated a-e, corresponding to
0-5 mol of phosphate per mol of S6, respectively (15). S6
phosphorylation was virtually undetectable in normal NIH
3T3 cells in the absence of serum but was stimulated by addi-
tion of 10% serum (Fig. 1 A and B). In ANN-1 cells, S6 was
phosphorylated in the absence of serum, indicating that
expression of the Ab-MuLV transforming gene product
causes S6 phosphorylation to occur constitutively (Fig. 1 C











FIG. 1. The effect of transformation by Ab-MuLV on S6 phos-
phorylation in the presence or absence of serum. NIH 3T3 cells and
ANN-1 cells were labeled with 32Pi in the presence or absence of
serum as described. Ribosomes were isolated, and the ribosomal
proteins were subjected to two-dimensional gel electrophoresis in
the presence of oocyte (unphosphorylated S6) and egg (phosphory-
lated S6) ribosomal carrier protein. The arrowhead marks the posi-
tion of unphosphorylated S6, and the letters a-e refer to S6 deriva-
tives with increasing numbers of phosphate groups, as judged by the
Coomassie blue staining pattern of the carrier protein. (A) NIH 3T3
fibroblasts in the absence of serum. (B) NIH 3T3 fibroblasts in the
presence of 1o serum. (C) ANN-1 cells in the absence of serum.
(D) ANN-1 cells in the presence of 10% serum.
Biochemistry: Maller et aL
Proc. NatL. Acad. Sci. USA 82 (1985)
tained 32P; in all derivatives of S6. No significance is at-
tached to the slightly greater level of total S6 phosphoryl-
ation after serum treatment of ANN-1 cells (Fig. 1D) be-
cause this was not apparent in other experiments of this
type.
After transformation of cells by retroviruses, a multitude
of cell parameters are altered (38). To determine whether the
constitutive phosphorylation of S6 in ANN-1 cells was an
effect of the Ab-MuLV-encoded kinase, we microinjected
into Xenopus oocytes a homogeneous preparation of the ki-
nase domain of the Ab-MuLV transforming protein. Follow-
ing microinjection, there was a significant increase in S6
phosphorylation relative to uninjected oocytes or oocytes in-
jected with the kinase buffer (data not shown). To determine
whether the microinjected Ab-MuLV kinase per se was re-
sponsible and not a trace contaminating activity, we microin-
jected partially purified preparations of Ab-MuLV kinase
from E. coli carrying a gene encoding either an active or an
inactive Ab-MuLV kinase. The 32p, content of S6 was in-
creased 15-fold in oocytes microinjected with extracts con-
taining the active kinase relative to oocytes injected with
buffer (Fig. 2, lanes 1 and 3). The slight increase (2-fold) in
the phosphorylation of S6 in response to injection of the ex-
tract containing the inactive Ab-MuLV kinase relative to in-
jection of buffer (Fig. 2, lanes 1 and 2) is probably a nonspe-
cific protein effect because bovine serum albumin also
causes a slight increase in S6 phosphorylation (33). This re-
sult indicates that the ability to cause S6 phosphorylation is a
specific property of the active Ab-MuLV protein kinase be-
cause the same E. coli proteins were injected in both the
control and experimental groups.
The Ab-MuLV-encoded protein kinase specifically phos-
phorylates tyrosine residues in vitro (2, 4); thus, the question
of the amino acid acceptor in the S6 protein was important.
In both normal NIH 3T3 fibroblasts grown in the presence of
serum and ANN-i cells grown without serum, and also in
oocytes induced to undergo maturation by treatment with
progesterone or microinjected with highly purified Ab-
MuLV kinase, phosphoserine was the only phosphoamino
acid detected in S6 (Fig. 3). Furthermore, incubation of 40S
ribosomal subunits with [y-32P]ATP and the Ab-MuLV ki-
nase did not result in phosphorylation of S6 in vitro (data not
shown). Thus, S6 is probably not a direct substrate for the
Ab-MuLV kinase in vivo.
To assess the number of phosphate residues incorporated
into oocyte S6 in response to microinjection ofhomogeneous
Ab-MuLV kinase, we examined the pattern of electrophoret-
ically separated 32Pi-labeled S6 derivatives on two-dimen-
sional gels (Fig. 4). In order to detect phosphorylated forms
of S6 from control oocytes (in which most of the S6 is in the
dephosphorylated form), it was necessary to develop the
autoradiograph considerably longer than the autoradiograph
of S6 from kinase-injected oocytes. Hence, the large in-
crease in the 32P, content of S6 after microinjection of the
Ab-MuLV kinase is not apparent in Fig. 4. In autoradio-
graphs of control (buffer-injected) oocytes, (Fig. 4B), the
small amount of phosphorylated S6 existed largely in the a,
b, and c forms (i.e., 1, 2, and 3 mol of phosphate per mol of
S6), whereas after microinjection of the kinase (Fig. 4A),
forms d and e (i.e., 4 and 5 mol of phosphate per mol of S6)
were also visible.















FIG. 2. S6 phosphorylation in oocytes after microinjection of ex-
tracts from E. coli carrying the Ab-MuLV kinase gene. Oocytes
were labeled with 32Pi for 4 hr, and Ab-MuLV kinase was partially
purified as described. Ribosomes were isolated from equal numbers
of oocytes 3 hr after injection, subjected to one-dimensional Na-
DodSO4 gel electrophoresis on 12.5% gels, and visualized by autora-
diography. Lanes: 1, buffer injection; 2, injection of an extract from
E. coli carrying a transformation- and kinase-deficient mutant; 3,
injection of an extract from E. coli carrying an active Ab-MuLV
kinase. The molecular weights of marker proteins are indicated. The
actual cpm in excised S6 bands were 98 (buffer), 231 (inactive ex-
tract), and 1476 (active extract).
FIG. 3. Phosphoamino acid analysis of phosphorylated S6. 32p_
labeled ribosomes were isolated from NIH 3T3 fibroblasts grown in
the presence of serum (lane A), from ANN-1 fibroblasts trans-
formed by Ab-MuLV in the absence of serum (lane B), from oocytes
treated with 10 ,uM progesterone (lane C), or oocytes injected with
Ab-MuLV kinase (lane D). The ribosomal proteins were separated
by electrophoresis through 12.5% NaDodSO4 gels, and the S6 band
was located by autoradiography, eluted, hydrolyzed in 6 M HCO at
100°C for 3 hr, and electrophoresed as described. The migration of
authentic coelectrophoresed phosphoamino acids was determined
by ninhydrin staining.
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FIG. 4. Two-dimensional gel electrophoresis of S6 from oocytes
after microinjection of Ab-MuLV kinase. 32P-labeled oocytes (150
per sample) were injected with either Ab-MuLV kinase (A) or buffer
(B); after 3 hr, ribosomes were isolated, the ribosomal proteins were
extracted, and two-dimensional gel electrophoresis was performed
as described under Materials and Methods except that no carrier
ribosomal proteins were added. The arrow marks the position of
unphosphorylated S6 as judged from the silver-staining pattern (15,
24). The derivatives a to e refer to S6 species with increasing num-
bers of phosphate groups. (A) Autoradiograph of S6 from oocytes
injected with Ab-MuLV kinase. (B) Autoradiograph of S6 from buff-
er-injected oocytes.
To determine whether the sites in S6 phosphorylated as a
result of the activity of the Ab-MuLV kinase in oocytes or in
ANN-1 cells were the same as in fibroblasts stimulated with
serum, we isolated ribosomes, labeled as in Figs. 1 and 4,
and separated their proteins by 1-dimensional gel electro-
phoresis. S6 was eluted and then treated with either trypsin
or chymotrypsin and analyzed by two-dimensional thin-layer
high-voltage electrophoresis. Previous studies of S6 phos-
phopeptides have utilized tryptic digests (35); but we find
that the use of chymotrypsin results in a more reproducible
pattern. The phosphopeptide maps of S6, with either trypsin
or chymotrypsin, were identical, regardless of whether S6
was isolated from normal cells in the presence of serum (Fig.
cA
a
5 A and C) or from Ab-MuLV-transformed cells in the ab-
sence of serum (Fig. 5 B and D). The phosphopeptide map of
S6 from oocytes microinjected with Ab-MuLV kinase was
equivalent to the pattern obtained with S6 from cells trans-
formed by Ab-MuLV (Fig. 5E); moreover, this map revealed
new phosphopeptides not apparent in control oocytes (Fig.
SF). Recently Blenis et al. (39) have demonstrated similar
phosphopeptides in S6 isolated from either RSV-trans-
formed or serum-stimulated chicken embryo fibroblasts.
DISCUSSION
It is evident that Xenopus oocytes can respond to a foreigp
transforming gene product by an increased phosphorylation
of ribosomal protein S6. Microinjection of a homogeneous
preparation of the Ab-MuLV kinase into oocytes resulted in
a 7- to 15-fold increase in the 32p; content of S6 and the for-
mation of S6 derivatives containing 4 and 5 mol of phosphate
per mol of S6. These results in oocytes support the idea that
S6 phosphorylation as observed in Ab-MuLV-transformed
cells in the absence of serum is a direct consequence of the
activity of the Ab-MuLV gene product. The data indicating
that an Ab-MuLV protein that is kinase-defective is unable
to increase S6 phosphorylation in oocytes are consistent
with the hypothesis that the tyrosine kinase activity of the
Ab-MuLV gene product is responsible for the stimulation of
S6 phosphorylation. We cannot rule out, however, the possi.
bility that other as yet unidentified activities of the Ab-
MuLV gene product are responsible. The normal Ab-MuLV
gene product is a fusion protein containing NH2-terminal se-
quences derived from the gag region of Mo-MuLV and se-
quences derived from the cellular c-abl gene, which encode













FIG. 5. Phosphopeptide analysis of S6. 32P-labeled ribosomes were isolated from NIH 3T3 fibroblasts labeled in the presence of 10% calf
serum, from Ab-MuLV-transformed cells (ANN-1) grown in the absence of serum, or from oocytes injected with Ab-MuLV kinase. The S6 was
isolated and digested, and the phosphopeptides were resolved as described. (A) Tryptic pattern from NIH 3T3 cells with 10%o serum. (B) Tryptic
pattern from ANN-1 cells in absence of serum. (C) Chymotryptic phosphopeptide pattern from NIH 3T3 cells in the presence of 10% serum. (D-)
Chymotryptic pattern from ANN-1 cells in the absence of serum. (E) Chymotryptic pattern of oocyte S6 3 hr after Ab-MuLV kinase injection.
(F) Chymotryptic pattern of oocyte S6 from control oocytes.
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in these studies lacks the gag region and instead has 80 ami-
no acids derived from the small tumor antigen of simian virus
40. Although this protein clearly retains an active tyrosine
kinase activity, the ability of this particular protein to trans-
form cells has not been investigated, and at least some of the
gag region is needed for efficient transformation of lym-
phoid cells by Ab-MuLV (40).
The stimulation of S6 phosphorylation in oocytes by the
Ab-MuLV kinase occurred at an intracellular kinase concen-
tration of about 50 nM, if one assumes 1 t1 of cell water.
Although we do not know the concentration of the Ab-
MuLV kinase in virally transformed cells, the intracellular
concentration of the cyclic AMP-dependent protein kinase,
which has been shown to phosphorylate S6 directly in re-
sponse to elevation of cyclic AMP (35, 41), is -1 4M (42).
The results of phosphopeptide mapping with either trypsin
or chymotrypsin suggest that microinjected Ab-MuLV ki-
nase induced the phosphorylation ofXenopus S6 at sites that
are identical to those in S6 isolated from ANN-1 cells in the
absence of serum or isolated from NIH 3T3 cells in the pres-
ence of serum (Fig. 5). This indicates that S6 must be highly
conserved in eukaryotic cells. Treatment of fibroblasts with
the tumor promoter phorbol ester, which is known to acti-
vate protein kinase C and induce S6 phosphorylation (43-
45), also results in phosphorylation of S6 at identical phos-
phopeptides (ref. 39; also our data, not shown). These analy-
ses indicate that there are no subclasses of sites uniquely
associated with the action of a single growth-promoting
agent. This conclusion is in agreement with that of Martin-
Perez et al. (35), who observed that treatment of Swiss
mouse 3T3 cells with either epidermal growth factor, insulin,
or prostaglandin F2a to cause partial S6 phosphorylation, in-
duces an identical pattern of S6 phosphopeptides. It cannot
be determined from these data, however, whether the same
enzymes are regulated under the various conditions, since
there are examples of proteins phosphorylated at the same
sites by distinct protein kinases (46).
Previous studies in 3T3 cells have suggested that each de-
rivative of phosphorylated S6, as separated by two-dimen-
sional gel electrophoresis, contains all the phosphopeptides
of the less phosphorylated derivative(s) plus one or more
unique peptides, implying that phosphorylation is ordered
(35). In the experiments presented here, control oocytes,
which appear to lack the two most highly phosphorylated
derivatives of S6 (Fig. 4B), also appear to lack several S6
phosphopeptides relative to control oocytes (compare Fig. 5
E and F), supporting the idea that in the oocyte system phos-
phorylation of the different sites may also occur in an or-
dered fashion. Although the phosphorylation of all sites in S6
is stimulated by the Ab-MuLV kinase in oocytes (Figs. 4 and
5), the phosphorylation of the additional sites relative to con-
trol oocytes suggests the possibility that an enzyme specific
for phosphorylation of certain sites in S6 is affected by the
Ab-MuLV kinase.
Formally, the increase in S6 phosphorylation induced by
the Ab-MuLV kinase may be explained by either an increase
in S6 seryl-protein kinase activity and/or a decrease in S6
protein phosphatase activity. Such an alteration in activity
could be a direct consequence of phosphorylation on tyro-
sine residues of an S6 kinase or S6 phosphatase, or there
could be a number of intermediate steps involved. Several
S6 protein kinases have been described (29, 41, 45, 47-50)
that are potential substrates for a direct effect of the Ab-
MuLV kinase.
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